SML0124
甲磺酸雷沙吉兰 甲磺酸酯
≥98% (HPLC), MAO B inhibitor, powder
别名:
(R)-N-2-丙炔基-1-氢化茚胺甲磺酸盐 甲磺酸酯, TVP-1012, 马来酸雷沙吉兰 甲磺酸酯
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C12H13N · CH4O3S
化学文摘社编号:
分子量:
267.34
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
甲磺酸雷沙吉兰 甲磺酸酯, ≥98% (HPLC)
Quality Level
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D +15 to +28°, c = 0.6 mg/mL in H2O
storage condition
desiccated
color
white to tan
solubility
H2O: ≥20 mg/mL
storage temp.
2-8°C
SMILES string
CS(O)(=O)=O.C#CCN[C@@H]1CCc2ccccc12
InChI
1S/C12H13N.CH4O3S/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12;1-5(2,3)4/h1,3-6,12-13H,7-9H2;1H3,(H,2,3,4)/t12-;/m1./s1
InChI key
JDBJJCWRXSVHOQ-UTONKHPSSA-N
Gene Information
human ... MAOB(4129)
Application
甲磺酸雷沙吉兰已被用于：
- 通过细胞凋亡调节因子Bax/Bcl-2的调节来检测其对视网膜色素变性（RP）的神经保护作用
- 在1-甲基-4-苯基-1,2,3,6-四氢吡啶（MPTP）诱导的小鼠模型中用作单胺氧化酶-B抑制剂
- 作为一种抗帕金森病药物，用于测试其对6-羟基多巴胺损伤的斑马鱼幼体运动迟缓和运动障碍样行为的拯救功能
甲磺酸雷沙吉兰可被用于MAO B型介导的细胞信号转导研究。
Biochem/physiol Actions
抗帕金森药物；MAO B抑制剂；抗凋亡；神经保护剂
甲磺酸雷沙吉兰是单胺氧化酶的一种不可逆抑制剂，其对B型MAO的选择性比A型高十四倍。它具有抗凋亡和神经保护活性，并已被用于治疗帕金森病。
甲磺酸雷沙吉兰是帕金森病早期的一种有效治疗选择。它可改善左旋多巴治疗患者的运动波动，并对此类患者可能是一种有用辅助手段。它具有神经保护作用并可增加多巴胺能神经元的存活。
Features and Benefits
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
商品
我们公司可提供多种组胺合成和代谢相关的产品，满足您的各类研究需求。
血清素（5-羟色胺）主要存在于三种主要细胞类型中：i）中杻神经系统（CNS）和肠肌间神经丛中的血清素能神经元，ii）胃肠道粘膜中的肠嗜铬细胞，和iii）血小板。血清素的代谢主要通过外部线粒体膜酶单胺氧化酶（MAO）进行，它以两种分子亚型存在，分别称为MAO-A和MAO-B。
Our company offers many products related to histamine synthesis and metabolism for your research needs.
Dhaval R Kalaria et al.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 127, 204-212 (2018-02-27)
Effective treatment of Parkinson's disease (PD) involves administration of therapeutic agents with complementary mechanisms of action in order to replenish, sustain or substitute endogenous dopamine. The objective of this study was to investigate anodal co-iontophoresis of pramipexole (PRAM; dopamine agonist)
O Rascol et al.
Lancet (London, England), 365(9463), 947-954 (2005-03-16)
Rasagiline mesylate is a novel drug for Parkinson's disease with selective, irreversible monoamine oxidase B (MAO-B) inhibitor activity, and is effective as monotherapy in early disease. This study investigated rasagiline efficacy and safety in levodopa-treated patients with Parkinson's disease and
Dannit Licht et al.
The Journal of pharmacy and pharmacology, 68(10), 1278-1289 (2016-07-29)
While bioequivalence between enteric-coated and immediate-release formulations can be achieved in terms of AUC, gastric emptying of enteric-coated dosage forms is a stochastic event, usually leading to lower Cmax values than those observed with the corresponding immediate release. This article
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML0124-10MG | 04061832948867 |
| SML0124-50MG | 04061832948874 |